AEON Biopharma Inc.
Organization details
- Legal name
- AEON Biopharma Inc.
- Former names
- Priveterra Acquisition Corp.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Aliso Viejo
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AEON
- Primary stock exchange
- NYSE American
Identifiers
- SEC CIK
- 0001837607
- EIN
- 85-3940478
Board of directors
-
Eric G. Carter · DirectorSince 2023
-
Jost Fischer · DirectorSince 2023
-
Marc Forth · Director · CHIEF EXECTUIVE OFFICERSince 2023
-
Robert E. Bancroft · Director · PRESIDENT & CEOSince 2025
-
Robert J. Palmisano · DirectorSince 2023
-
Seongsoo Park · DirectorSince 2024
-
Shelley B. Thunen · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 13, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
0.3%
-
0.3%
Board connections
2 of this board's directors also sit on 2 other boards. 2 are in the same sector.
-
LENZ Therapeutics Inc. Same sectorvia Shelley B. Thunen
-
RxSight Inc. Same sectorvia Robert J. Palmisano
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $241,500
- 1 purchase by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 30, 2026 | Daewoong Co., Ltd 10% owner | In-the-money exercise | +11,236,631 | $0.00 | $1,124 |
| Oct 30, 2026 | Daewoong Co., Ltd 10% owner | Other | −3,822 | $0.29 | $1,124 |
| Aug 19, 2026 | LYNCH TIMOTHY P 10% owner | Open-market purchase | +1,150,000 | $0.21 | $241,500 |
| Jun 17, 2026 | Shelley B. Thunen Director | Grant or award | +222,684 | — | — |
| Jun 17, 2026 | Robert J. Palmisano Director | Grant or award | +222,684 | — | — |
| Jun 17, 2026 | Marc Forth Director | Grant or award | +222,684 | — | — |
| Jun 17, 2026 | Jost Fischer Director | Grant or award | +222,684 | — | — |
| Jun 17, 2026 | Eric G. Carter Director | Grant or award | +222,684 | — | — |
| Apr 2, 2026 | John Bencich Officer (CHIEF FINANCIAL OFFICER) | Grant or award | +754,717 | — | — |
| Mar 4, 2026 | Oh Chad Officer (CHIEF MEDICAL OFFICER) | Grant or award | +1,316,872 | — | — |
| Mar 4, 2026 | Wilson Alexander Blair Officer (CLO, CSO, and Corp Secretary) | Grant or award | +1,316,872 | — | — |
| Mar 4, 2026 | Sy Jennifer Officer (PRINCIPAL ACCOUNTING OFFICER) | Grant or award | +925,925 | — | — |
| Feb 17, 2026 | Oh Chad Officer (CHIEF MEDICAL OFFICER) | Grant or award | +862,500 | — | — |
| Feb 17, 2026 | Wilson Alexander Blair Officer (CLO, CSO, and Corp Secretary) | Grant or award | +862,500 | — | — |
| Feb 17, 2026 | Sy Jennifer Officer (PRINCIPAL ACCOUNTING OFFICER) | Grant or award | +575,000 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about AEON Biopharma Inc.
Who is the CEO of AEON Biopharma Inc.?
Robert E. Bancroft has been AEON Biopharma Inc.'s President & CEO since April 2025.
How many directors are on AEON Biopharma Inc.'s board?
AEON Biopharma Inc.'s board has 7 directors: Eric G. Carter, Jost Fischer, Marc Forth, Robert E. Bancroft, Robert J. Palmisano, Seongsoo Park and Shelley B. Thunen.
Are AEON Biopharma Inc. insiders buying or selling shares?
Over the last 12 months, AEON Biopharma Inc. insiders bought $241,500 of shares in 1 purchase and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="aeon-biopharma-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.